Bupropion Dosing and Clinical Guidelines
Depression and ADHD Dosing
- Initiate therapy with 150 mg once daily in the morning for the first 3 days, then increase to 150 mg twice daily if tolerated, with a maximum of 300 mg per day in divided doses; the second dose should be taken before 3 PM to reduce insomnia risk【1】【2】【4】.
Smoking‑Cessation Dosing
- Begin bupropion 1–2 weeks before the planned quit date.
- Days 1–3: 150 mg once daily.
- Days 4–7 through week 12: 150 mg twice daily if tolerated, maximum 300 mg/day.
Standard treatment duration is 7–12 weeks, which may be extended to 6–12 months to support continued abstinence【4】【1】【2】.
Bupropion can be combined with nicotine‑replacement therapy to enhance cessation efficacy【1】【2】.
Absolute Contraindications
- History of seizure disorder or any condition that lowers the seizure threshold (e.g., stroke, brain metastases, eating disorders).
- Current or recent (within 14 days) use of monoamine‑oxidase inhibitors.
- Abrupt discontinuation of alcohol or benzodiazepines.
- Closed‑angle glaucoma.
- Concurrent tamoxifen therapy (bupropion inhibits CYP2D6, reducing tamoxifen effectiveness)【4】【1】【2】【3】.
Critical Safety Monitoring
- Highest risk period: first 1–2 months of therapy; monitor intensively for suicidal ideation, agitation, irritability, akathisia, worsening anxiety, panic, hostility, impulsivity, or worsening depression【3】【4】.
Response Assessment Timeline
- Initial improvement (energy/activation) may be observed within days to weeks.
- A full therapeutic trial requires 4–8 weeks at an adequate dose.
- Formal reassessment is recommended at 6–8 weeks to determine adequacy; do not deem the medication ineffective before completing this period【3】.
Common Adverse Effects (150 mg twice daily)
- Loss of appetite, insomnia, anxiety, agitation.
Dry mouth, headache, nausea, constipation, tremor【3】.
Seizure risk: 10 cases reported among 13 000 participants when dosed appropriately【5】.
Clinical Advantages Over SSRIs
- Significantly lower sexual‑dysfunction rates (≈ 8 % vs 18–30 % with SSRIs)【3】.
- Activating properties beneficial for patients with low energy, apathy, or fatigue【3】.
- No serotonergic activity, thus no risk of serotonin syndrome【ignore ref】.
- Dual benefit for patients with comorbid smoking and depression【3】.
Preferred Clinical Scenarios for Bupropion
- Patients with comorbid smoking and depression/ADHD.
- Individuals concerned about sexual side effects of SSRIs.
- Patients whose primary symptom is fatigue or low energy.
- Concurrent obesity and depression (consider the naltrexone/bupropion combination)【3】.
Situations to Avoid Bupropion
- Agitated depression (bupropion may exacerbate agitation).
- Any seizure history or risk factors (absolute contraindication).
- Concurrent opioid therapy when using the naltrexone/bupropion combination.
- Tamoxifen therapy (due to CYP2D6 inhibition)【4】【3】【1】【2】.
Formulation‑Specific Considerations
- Sustained‑Release (SR): twice daily; second dose before 3 PM【1】【2】【3】.
- Extended‑Release (XL): once daily in the morning【3】.
Immediate‑Release (IR): three times daily【ignore ref】.
Formulations are bioequivalent but not interchangeable; each requires its specific dosing schedule【3】.
Maintenance Therapy Duration
- After remission of a first depressive episode, continue bupropion for 4–9 months to reduce relapse risk.
- For recurrent depression, a longer maintenance period is recommended【3】.
Obesity Treatment (Naltrexone/Bupropion) – Titration Schedule
| Week | Dose (Bupropion / Naltrexone) | Administration |
|---|---|---|
| 1 | 90 mg / 8 mg | Once daily in the morning |
| 2 | 90 mg / 8 mg | Twice daily |
| 3 | 180 mg / 16 mg (AM) + 90 mg / 8 mg (PM) | Morning and afternoon |
| ≥4 | 180 mg / 16 mg | Twice daily (maintenance) |
- The second dose should not be taken late in the day to minimize insomnia【3】.
- Discontinue the combination if < 5 % weight loss after 12 weeks at the maintenance dose【3】.